RecruitingNCT06727370
Cognitive Screening in Lung Cancer Patients
Sponsor
European Institute of Oncology
Enrollment
200 participants
Start Date
Jan 10, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
Exclusion Criteria5
- Age ≥ 70
- Presence of brain metastases
- Patients with concomitant neurological or psychiatric disorders.
- Patients undergoing brain radiotherapy
- Previous diagnosis of lung cancer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06727370
Related Trials
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
NCT048263411 location
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784129 locations
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT068355699 locations
Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1
NCT071222581 location
Study of XB010 in Subjects With Solid Tumors
NCT0654533117 locations